Nuro's latest partnership in Houston is allowing prescription and essentials to be delivered to Houstonians across three ZIP codes. Photo courtesy of Nuro

The latest partnership from California-based Nuro, which has a fleet of driverless vehicles in Houston, means prescription drug delivery to certain parts of Houston.

Rhode Island-based CVS Pharmacy will offer the delivery option for prescriptions and essentials for free beginning in June for three ZIP codes near a CVS location in Bellaire (5430 Bissonnet St., Bellaire, TX 77401).

"We are seeing an increased demand for prescription delivery," says Ryan Rumbarger, senior vice president of store operations at CVS Health, in a release. "We want to give our customers more choice in how they can quickly access the medications they need when it's not convenient for them to visit one of our pharmacy locations."

The driverless delivery option will be made available through the CVS app, and recipients will have to prove their identity to retrieve their order.

Nuro has been expanding throughout the Houston market for over a year now — first entering the Houston market with its Kroger pilot program, but this partnership represents a whole new sector for the robotics company.

"Today, we are excited to expand into an entirely new vertical: health," says Dave Ferguson, Nuro's co-founder and president, in the release. "Through our partnership with CVS, we hope to make it easier for customers to get medicine, prescriptions, and the other things they need delivered directly to their homes."

Following Nuro's initial deal with Kroger, the company expanded to pizza delivery with Domino's Pizza before forming agreement with Walmart. Earlier this year, the company received approval from the United States Department of Transportation's National Highway Traffic Safety Administration that allowed Nuro's vehicles on public roads without the features of traditional, passenger-carrying vehicles — like side mirrors or windshields, for instance.

In January, InnovationMap spoke with Sola Lawal, Nuro product operations manager in Houston, and asked him about what types of partnerships Nuro is targeting.

"The way that we think about this is that this new technology and our mission of accelerating robotics for everyday life, is we will bring the people what they want," Lawal told InnovationMap.

And as far as continuing to expand in Houston, the city's diversity, varied roadscapes, and regulatory support makes it prime for robotics and self-driving technology.

"Houston is our first full-scale operations city," said Lawal. "All eyes at Nuro are focused on Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.